Results 21 to 30 of about 276,260 (291)

IgE‐cross‐blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1

Allergy. European Journal of Allergy and Clinical Immunology, 2021
Evidence has accumulated that birch pollen immunotherapy reduces rhinoconjunctivitis to pollen of birch homologous trees. Therapeutic efficacy has been associated with IgE‐blocking IgG antibodies. We have recently shown that sera collected after 16 weeks
JoãoRodrigues Grilo, C. Kitzmüller, L. Aglas, Gabriela Sánchez Acosta, U. Vollmann, C. Ebner, F. Horak, T. Kinaciyan, C. Radauer, F. Ferreira, B. Jahn-Schmid, B. Bohle   +11 more
semanticscholar   +1 more source

Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir

Frontiers in Immunology, 2021
Allergen immunotherapy (AIT) is the only disease-modifying treatment for allergic disorders that induces immunological tolerance through administration of specific allergens.
S. Baba, R. Rasool, Ayaz Gull, T. Qureshi, A. H. Beigh, Qurteeba Qadri, Z. Shah   +6 more
semanticscholar   +1 more source

Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children

Allergy. European Journal of Allergy and Clinical Immunology, 2023
Allergic rhinitis (AR) is a chronic inflammatory disease of the upper airway, which progresses into allergic asthma (AA) in up to 45% of children. This analysis aimed to investigate clinical and economic benefits of sublingual allergen immunotherapy ...
E. Hamelmann, Eva Hammerby, Katrine Skaarup Scharling, Mikkel Pedersen, A. Okkels, J. Schmitt   +5 more
semanticscholar   +1 more source

First‐in‐human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Polymerized allergens conjugated to non‐oxidized mannan (PM‐allergoids) are novel vaccines targeting dendritic cells (DCs). Previous experimental data indicate that PM‐allergoids are readily taken up by DCs and induce Treg cells.
A. Nieto, A. Mazon, M. Nieto, Ethel Ibáñez, D. Jang, S. Calaforra, P. Alba, C. Pérez-Francés, R. Llusar, J. Montoro, Antonio de Mateo, R. Alamar, D. El-Qutob, Javier Fernández, L. Moral, T. Toral, M. Antón, C. Andréu, Á. Ferrer, Isabel Flores, Neus Cerdá, Sandra del Pozo, R. Caballero, J. Subiza, M. Casanovas   +24 more
semanticscholar   +1 more source

ORALAIR: A novel sublingual immunotherapy

Journal of Mahatma Gandhi Institute of Medical Sciences, 2016
Arpita Singh, Ankit Bhatia, Ved Prakash, Ajay Kumar Verma, Surya Kant, Anand Srivastava, Darshan Kumar Bajaj   +6 more
doaj   +2 more sources

Sublingual immunotherapy: World Allergy Organization position paper 2013 update

World Allergy Organization Journal, 2014
We have prepared this document, “Sublingual Immunotherapy: World Allergy Organization Position Paper 2013 Update”, according to the evidence-based criteria, revising and updating chapters of the originally published paper, “Sublingual Immunotherapy ...
Giorgio Walter Canonica, Linda Cox, Ruby Pawankar, Carlos E. Baena-Cagnani, Michael Blaiss, Sergio Bonini, Jean Bousquet, Moises Calderón, Enrico Compalati, Stephen R. Durham, Roy Gerth van Wijk, Désirée Larenas-Linnemann, Harold Nelson, Giovanni Passalacqua, Oliver Pfaar, Nelson Rosário, Dermot Ryan, Lanny Rosenwasser, Peter Schmid-Grendelmeier, Gianenrico Senna, Erkka Valovirta, Hugo Van Bever, Pakit Vichyanond, Ulrich Wahn, Osman Yusuf   +24 more
doaj   +1 more source

The future outlook on allergen immunotherapy in children: 2018 and beyond. [PDF]

, 2018
Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases.
Arasi S, Corsello G, Pajno GB, Villani A
core   +2 more sources

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis [PDF]

, 2013
© Queen’s Printer and Controller of HMSO 2013Severe allergic rhinitis uncontrolled by conventional medication can substantially affect quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim of reducing
Barton, P, Dretzke, J, Fry-Smith, A, Huissoon, A, Kaambwa, B, Meadows, A, Meads, C, Novielli, N   +7 more
core   +1 more source

Positive and negative AIT trials: What makes the difference? [PDF]

, 2018
Background: Allergen immunotherapy has proven to be efficacious in allergic rhinitis and asthma. However, results from randomised clinical trials may vary substantially. Clinical trials may unexpectedly fail.
Gerth van Wijk, R. (Roy)
core   +7 more sources

Critical appraisal of the clinical utility of sublingual immunotherapy in allergy

Contemporary Clinical Trials Communications, 2016
Since it was introduced by Noon in 1911, allergen-specific immunotherapy or desensitization has been widely prescribed in the management of allergic diseases. Aimed at the etiology, it represents the only effective treatment for allergy.
S. Aissa, R. Ben Jazia, J. Ayachi, C. Ben Salem, A. Hayouni, A. Abdelghani, H. Ben Saad, M. Boussarsar   +7 more
doaj   +1 more source